

**AMETEK, Inc.**  
**Reconciliations of Non-GAAP Financial Measures (Unaudited)**

**EBITDA**

EBITDA represents earnings before interest, income taxes, depreciation and amortization. EBITDA is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. It should not be considered, however, as an alternative to operating income as an indicator of the Company's operating performance or as an alternative to cash flows as a measure of the Company's overall liquidity as presented in the Company's consolidated financial statements. The table below presents the reconciliation of net income reported in accordance with U.S. GAAP to EBITDA.

(In millions)	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2024	Year Ended December 31,		
			2023	2022	2021
Net income.....	\$ 988.9	\$ 340.2	\$ 1,313.2	\$ 1,159.5	\$ 990.1
Add (deduct):					
Interest expense.....	91.0	25.1	81.8	83.2	80.4
Interest income.....	(4.7)	(1.3)	(11.1)	(1.7)	(1.4)
Income taxes.....	228.3	78.6	293.2	269.2	233.1
Depreciation.....	101.7	30.6	122.5	113.7	108.5
Amortization.....	185.3	59.8	215.1	205.8	183.6
EBITDA.....	<u>\$ 1,590.5</u>	<u>\$ 533.0</u>	<u>\$ 2,014.7</u>	<u>\$ 1,829.7</u>	<u>\$ 1,594.3</u>
Add: Paragon integration costs.....	29.20	-	-	-	-
Adjusted EBITDA.....	<u>\$ 1,619.7</u>	<u>\$ 533.0</u>	<u>\$ 2,014.7</u>	<u>\$ 1,829.7</u>	<u>\$ 1,594.3</u>

**FREE CASH FLOW**

Free cash flow represents cash flow from operating activities less capital expenditures. Free cash flow is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. (Also see EBITDA headnote above). The table below presents the reconciliation of cash flow from operating activities reported in accordance with U.S. GAAP to free cash flow.

(In millions)	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2024	Year Ended December 31,		
			2023	2022	2021
Cash provided by operating activities.....	\$ 1,278.8	\$ 487.2	\$ 1,735.3	\$ 1,149.4	\$ 1,160.5
Deduct: Capital expenditures.....	(75.4)	(26.3)	(136.2)	(139.0)	(110.7)
Free cash flow.....	<u>\$ 1,203.4</u>	<u>\$ 460.9</u>	<u>\$ 1,599.1</u>	<u>\$ 1,010.4</u>	<u>\$ 1,049.8</u>

**NET DEBT AS A PERCENTAGE OF CAPITALIZATION**

Net debt represents total debt, net minus cash and cash equivalents. Net debt is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. (Also see EBITDA headnote above). The table below presents the reconciliation of total debt, net reported in accordance with U.S. GAAP to net debt.

(In millions)	September 30, 2024	December 31,		
		2023	2022	2021
Total debt, net.....	\$ 2,336.5	\$ 3,313.3	\$ 2,385.0	\$ 2,544.2
Less: Cash and cash equivalents.....	(396.3)	(409.8)	(345.4)	(346.8)
Net debt.....	1,940.2	2,903.5	2,039.6	2,197.4
Stockholders' equity.....	9,550.2	8,730.2	7,476.5	6,871.9
Capitalization (net debt plus stockholders' equity).....	<u>\$ 11,490.4</u>	<u>\$ 11,633.7</u>	<u>\$ 9,516.1</u>	<u>\$ 9,069.3</u>
Net debt as a percentage of capitalization.....	<u>16.9%</u>	<u>25.0%</u>	<u>21.4%</u>	<u>24.2%</u>

**Reconciliations of GAAP to Non-GAAP Financial Measures**  
(In thousands, except per share amounts)  
(Unaudited)

	2023	2022	2021	2020	2019	2018	2017	2016	2015 <sup>(1)</sup>	2014 <sup>(1)</sup>
EIG Segment operating income (GAAP)	\$ 1,310,962	\$ 1,089,729	\$ 958,183	\$ 770,620	\$ 865,307	\$ 782,144	\$ 671,646	\$ 571,077	\$ 639,399	\$ 612,992
Realignment costs	-	-	-	22,846	-	-	4,534	12,355	18,518	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	9,200	-	-
Zygo integration costs	-	-	-	-	-	-	-	-	-	18,877
Adjusted EIG Segment operating income (Non-GAAP)	<u>\$ 1,310,962</u>	<u>\$ 1,089,729</u>	<u>\$ 958,183</u>	<u>\$ 793,466</u>	<u>\$ 865,307</u>	<u>\$ 782,144</u>	<u>\$ 676,180</u>	<u>\$ 592,632</u>	<u>\$ 657,917</u>	<u>\$ 631,869</u>
EMG Segment operating income (GAAP)	\$ 496,569	\$ 503,593	\$ 437,378	\$ 324,962	\$ 387,931	\$ 363,765	\$ 306,779	\$ 274,234	\$ 318,098	\$ 335,046
Realignment costs	-	-	-	20,890	-	-	12,252	11,644	17,298	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	4,700	-	-
Adjusted EMG Segment operating income (Non-GAAP)	<u>\$ 496,569</u>	<u>\$ 503,593</u>	<u>\$ 437,378</u>	<u>\$ 345,852</u>	<u>\$ 387,931</u>	<u>\$ 363,765</u>	<u>\$ 319,031</u>	<u>\$ 290,578</u>	<u>\$ 335,396</u>	<u>\$ 335,046</u>
Operating income (GAAP)	\$ 1,707,459	\$ 1,500,692	\$ 1,308,670	\$ 1,027,884	\$ 1,177,380	\$ 1,075,540	\$ 903,620	\$ 790,979	\$ 907,716	\$ 898,586
Realignment costs	-	-	-	43,928	-	-	16,786	25,556	36,605	-
Charitable donations	-	-	-	-	-	-	5,000	-	-	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	13,900	-	-
Zygo integration costs	-	-	-	-	-	-	-	-	-	18,877
Adjusted Operating income (Non-GAAP)	<u>\$ 1,707,459</u>	<u>\$ 1,500,692</u>	<u>\$ 1,308,670</u>	<u>\$ 1,071,812</u>	<u>\$ 1,177,380</u>	<u>\$ 1,075,540</u>	<u>\$ 925,406</u>	<u>\$ 830,435</u>	<u>\$ 944,321</u>	<u>\$ 917,463</u>
Diluted earnings per share (GAAP)	\$ 5.67	\$ 5.01	\$ 4.25	\$ 3.77	\$ 3.75	\$ 3.34	\$ 2.94	\$ 2.19	\$ 2.45	\$ 2.37
Realignment costs	-	-	-	0.19	-	-	0.07	0.11	0.15	-
Income tax benefit on realignment costs	-	-	-	(0.04)	-	-	(0.02)	(0.04)	(0.05)	-
Charitable donations	-	-	-	-	-	-	0.02	-	-	-
Income tax benefit on charitable donations	-	-	-	-	-	-	(0.01)	-	-	-
Net deferred tax revaluation due to Tax Reform	-	-	-	-	-	(0.01)	(0.80)	-	-	-
Deemed repatriation of foreign earnings due to Tax Reform	-	-	-	-	-	(0.04)	0.41	-	-	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	0.06	-	-
Income tax benefit on indefinite-lived intangibles impairment	-	-	-	-	-	-	-	(0.02)	-	-
Zygo integration costs	-	-	-	-	-	-	-	-	-	0.07
Income tax benefit on Zygo integration costs	-	-	-	-	-	-	-	-	-	(0.02)
Gain from sale of Reading Alloys	-	-	-	(0.61)	-	-	-	-	-	-
Income tax charge on gain on sale of Reading Alloys	-	-	-	0.14	-	-	-	-	-	-
Pretax amortization of acquisition-related intangible assets	0.93	0.89	0.79	0.67	0.58	0.49	0.44	0.45	0.33	0.30
Income tax benefit on amortization of acquisition-related intangible assets	(0.22)	(0.22)	(0.19)	(0.16)	(0.14)	(0.12)	(0.15)	(0.16)	(0.11)	(0.10)
Rounding	-	-	-	(0.01)	-	-	-	-	-	-
Adjusted Diluted earnings per share (Non-GAAP)	<u>\$ 6.38</u>	<u>\$ 5.68</u>	<u>\$ 4.85</u>	<u>\$ 3.95</u>	<u>\$ 4.19</u>	<u>\$ 3.66</u>	<u>\$ 2.90</u>	<u>\$ 2.59</u>	<u>\$ 2.77</u>	<u>\$ 2.62</u>
EIG Segment operating margin (GAAP)	28.3%	25.8%	25.5%	25.8%	26.0%	25.8%	25.0%	24.2%	26.5%	25.3%
Realignment costs	-	-	-	0.7	-	-	0.1	0.5	0.7	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	0.4	-	-
Zygo integration costs	-	-	-	-	-	-	-	-	-	0.8
Adjusted EIG Segment operating margin (Non-GAAP)	<u>28.3%</u>	<u>25.8%</u>	<u>25.5%</u>	<u>26.5%</u>	<u>26.0%</u>	<u>25.8%</u>	<u>25.1%</u>	<u>25.1%</u>	<u>27.2%</u>	<u>26.1%</u>
EMG Segment operating margin (GAAP)	25.2%	26.2%	24.5%	21.0%	21.1%	20.0%	19.1%	18.5%	20.4%	20.9%
Realignment costs	-	-	-	1.3	-	-	0.8	0.8	1.1	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	0.3	-	-
Adjusted EMG Segment operating margin (Non-GAAP)	<u>25.2%</u>	<u>26.2%</u>	<u>24.5%</u>	<u>22.3%</u>	<u>21.1%</u>	<u>20.0%</u>	<u>19.9%</u>	<u>19.6%</u>	<u>21.5%</u>	<u>20.9%</u>
Operating income margin (GAAP)	25.9%	24.4%	23.6%	22.6%	22.8%	22.2%	21.0%	20.6%	22.8%	22.3%
Realignment costs	-	-	-	1.0	-	-	0.4	0.7	1.0	-
Charitable donations	-	-	-	-	-	-	0.1	-	-	-
Indefinite-lived intangibles impairment	-	-	-	-	-	-	-	0.3	-	-
Zygo integration costs	-	-	-	-	-	-	-	-	-	0.5
Adjusted Operating income margin (Non-GAAP)	<u>25.9%</u>	<u>24.4%</u>	<u>23.6%</u>	<u>23.6%</u>	<u>22.8%</u>	<u>22.2%</u>	<u>21.5%</u>	<u>21.6%</u>	<u>23.8%</u>	<u>22.8%</u>

(1) - Amounts do not include the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*.

**AMETEK, Inc.**  
**Reconciliations of GAAP to Non-GAAP Financial Measures**  
(Unaudited)

	Diluted Earnings Per Share										Forecasted Diluted Earnings Per Share											
	Three Months Ended				Year Ended	Three Months Ended				Year Ended	Three Months Ended				Year Ended	Three Months Ended			Year Ended			
	March 31,	June 30,	Sep. 30,	Dec. 31,		March 31,	June 30,	Sep. 30,	Dec. 31,		March 31,	June 30,	Sep. 30,	Dec. 31,		March 31,	June 30,	Sep. 30,	December 31,	Low	High	Low
	2021	2021	2021	2021	2021	2022	2022	2022	2022	2022	2023	2023	2023	2023	2023	2024	2024	2024	2024	2024	2024	2024
Diluted earnings per share (GAAP)	\$ 0.94	\$ 1.00	\$ 1.10	\$ 1.21	\$ 4.25	\$ 1.17	\$ 1.22	\$ 1.29	\$ 1.33	\$ 5.01	\$ 1.32	\$ 1.40	\$ 1.47	\$ 1.48	\$ 5.67	\$ 1.34	\$ 1.45	\$ 1.47	\$ 1.61	\$ 1.66	\$ 5.86	\$ 5.91
Pretax amortization of acquisition-related intangible assets	0.17	0.20	0.21	0.21	0.79	0.21	0.21	0.21	0.25	0.89	0.22	0.22	0.22	0.26	0.93	0.27	0.27	0.26	0.27	0.27	1.07	1.07
Income tax benefit on amortization of acquisition-related intangible assets	(0.04)	(0.05)	(0.05)	(0.05)	(0.19)	(0.05)	(0.05)	(0.05)	(0.06)	(0.22)	(0.05)	(0.05)	(0.05)	(0.06)	(0.22)	(0.06)	(0.06)	(0.06)	(0.07)	(0.07)	(0.26)	(0.26)
Paracon integration costs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.13	-	-	-	-	0.13	0.13
Income tax benefit on Paracon integration costs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(0.03)	-	-	-	-	(0.03)	(0.03)
Rounding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(0.01)	-	(0.01)	-	-	-	-
Adjusted Diluted earnings per share (Non-GAAP)	<u>\$ 1.07</u>	<u>\$ 1.15</u>	<u>\$ 1.26</u>	<u>\$ 1.37</u>	<u>\$ 4.85</u>	<u>\$ 1.33</u>	<u>\$ 1.38</u>	<u>\$ 1.45</u>	<u>\$ 1.52</u>	<u>\$ 5.68</u>	<u>\$ 1.49</u>	<u>\$ 1.57</u>	<u>\$ 1.64</u>	<u>\$ 1.68</u>	<u>\$ 6.38</u>	<u>\$ 1.64</u>	<u>\$ 1.66</u>	<u>\$ 1.66</u>	<u>\$ 1.81</u>	<u>\$ 1.86</u>	<u>\$ 6.77</u>	<u>\$ 6.82</u>

**Use of Non-GAAP Financial Information**

The Company supplements its consolidated financial statements presented on a U.S. generally accepted accounting principles ("GAAP") basis with certain non GAAP financial information to provide investors with greater insight, increased transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Reconciliation of non GAAP measures to their most directly comparable GAAP measures are included in the accompanying financial tables. These non GAAP financial measures should be considered in addition to, and not as a replacement for, or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.

The Company believes that these measures provide useful information to investors by reflecting additional ways of viewing AMETEK's operations that, when reconciled to the comparable GAAP measure, helps our investors to better understand the long-term profitability trends of our business, and facilitates easier comparisons of our profitability to prior and future periods and to our peers.